Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511792 | 0.92 | MYC (0.38) | GRM5 | |
| SCHEMBL24801556 | 0.90 | S1PR5 (0.37) | GRM5S1PR5CYP1A2HRH4 | |
| SCHEMBL26171399 | 0.90 | S1PR5 (0.46) | GRM5S1PR5CYP1A2 | |
| SCHEMBL29134195 | 0.90 | GRM5 (0.36) | GRM5S1PR5CYP1A2HRH4GRM3 | |
| SCHEMBL30694252 | 0.89 | GRM5 (0.38) | GRM5S1PR5CYP1A2HRH4 | |
| SCHEMBL29021196 | 0.87 | ALDH1A1 (0.41) | GRM5HRH4GRM3 | |
| SCHEMBL26171398 | 0.86 | S1PR5 (0.39) | GRM5S1PR5MCL1BAK1 | |
| SCHEMBL31312913 | 0.84 | LRRK2 (0.37) | GRM5S1PR5 | |
| SCHEMBL26003250 | 0.84 | LRRK2 (0.37) | GRM5S1PR5 | |
| SCHEMBL29021233 | 0.84 | HRH4 (0.38) | GRM5HRH4GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466262-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2024-11-27 | — | — | EP | disclosed |
| US-20240368203-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2024-11-07 | — | — | US | disclosed |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-17 | — | — | US | disclosed |
| EP-4444724-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BeiGene Switzerland GmbH (CH) | 2024-10-16 | — | — | EP | disclosed |
| CN-118696038-A | EGFR degradation by conjugation of EGFR inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118488958-A | Compounds for degrading EGFR kinase | 百济神州有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023138607-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE , LTD. (KY) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023098656-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023098656-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368203-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | GRM5 3163/4885S1PR5 4304/4885ADORA1 4576/4885 |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | GRM5 3226/4885S1PR5 4145/4885ADORA1 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.